Watch for patterns: headache, dizziness, nausea, diarrhea, constipation, or fatigue
In the 72-week STEP UP trial, in adults with obesity along with diet and exercise, Wegovy HD (semaglutide) injection 7.2 mg significantly reduced body weight 1 * Analysis of all patients regardless of if they stayed on treatment 7 Co-primary end point: Percent change in body weight 1* Co-primary end point: Reduction in body weight of 5% 1 * Proportion of patients achieving 5% weight loss at 72 weeks * Confirmatory secondary end points (week 72) 1 * 10% weight loss: 79.8% Wegovy HD vs 20.3% placebo 15% weight loss: 63.8% Wegovy HD vs 7.5% placebo 20% weight loss: 45.5% Wegovy HD vs 2.8% placebo ~1 in 3 people (31.2%) of patients achieved 7 * vs 0% of patients with placebo If all patients stayed on treatment 7 20.7% mean weight loss with Wegovy HD vs 2.4% (6 lb) placebo at 72 weeks, in an idealized scenario estimating efficacy if patients remained on treatment for the duration of the trial and used no other weight-loss therapies 7 Mean baseline body weight: Wegovy HD=247.8 lb
Pricing Implications and Market Dynamics The cost-of-goods advantage of small-molecule manufacturing does not automatically translate into lower retail pricing, as pharmaceutical pricing is determined by factors including development costs, market competition, patent protection, payer negotiations, and value-based pricing frameworks
I've done this before
- For mobility aid use, include devices such as cane, walker, wheelchair, rollator, crutches, prosthesis, or other assistive ambulation aids
In December 2023, Medifast partnered with LifeMD, an online primary care platform, to integrate GLP-1 management and prescribing features into its Optavia weight loss program
